RESILIA PHARMACEUTICALS
Live / Registered — Registered (as of 24 Oct 2023)
What this means for you
Registered since 24 Oct 2023. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (next due by 24 Oct 2029: the §8 declaration of use).
Record
- Serial number
- 90448104
- Registration number
- 7202460
- Mark type
- Word mark
- Filed
- 05 Jan 2021
- Published for opposition
- 07 Dec 2021
- Registered
- 24 Oct 2023
- Next maintenance filing
- §8 declaration of use, due by 24 Oct 2029 (grace period to 24 Apr 2030)
- Attorney of record
- Julie Beth Albert
Goods and services
- Class 005 — Pharmaceuticals: Dermatological pharmaceutical products; Pharmaceutical skin lotions; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for treating skin disorders
Owner
- Peak Pharma Commercial Partners, LLC, New York, NY, US
- Peak Pharma Commercial Partners, LLC, New York, NY, US
- Peak Pharma Commercial Partners, LLC, New York, NY, US
Prosecution history
- 24 Oct 2023 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 24 Oct 2023 — REGISTERED-PRINCIPAL REGISTER
- 19 Sept 2023 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 16 Sept 2023 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 14 Sept 2023 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 14 Sept 2023 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 14 Sept 2023 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 22 Jun 2023 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 22 Jun 2023 — NON-FINAL ACTION E-MAILED
- 22 Jun 2023 — SU - NON-FINAL ACTION - WRITTEN
- 01 Jun 2023 — STATEMENT OF USE PROCESSING COMPLETE
- 08 May 2023 — USE AMENDMENT FILED
- 30 May 2023 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 30 May 2023 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 08 May 2023 — TEAS STATEMENT OF USE RECEIVED